特发性肺纤维化
Idiopathic pulmonary fibrosis
定义 英文原文（暂无中文）
An interstitial lung disease with a poor prognosis, that is characterized by the progressive formation of scar tissue within the lungs in the absence of any known cause.
别名
隐原性致纤维化性肺泡炎
基本事实
- 遗传方式
- 多基因/多因素
- 发病年龄
- 成年期
- 患病率
- 1-5 / 10 000
相关基因 14
| 基因 | 名称 | 关联类型 |
|---|---|---|
| SFTPA1 | surfactant protein A1 | Major susceptibility factor in |
| SFTPC | surfactant protein C | Major susceptibility factor in |
| DSP | desmoplakin | Major susceptibility factor in |
| TERT | telomerase reverse transcriptase | Major susceptibility factor in |
| TERC | telomerase RNA component | Major susceptibility factor in |
| ABCA3 | ATP binding cassette subfamily A member 3 | Candidate gene tested in |
| MUC5B | mucin 5B, oligomeric mucus/gel-forming | Major susceptibility factor in |
| SFTPA2 | surfactant protein A2 | Major susceptibility factor in |
| RTEL1 | regulator of telomere elongation helicase 1 | Major susceptibility factor in |
| FAM13A | family with sequence similarity 13 member A | Major susceptibility factor in |
| STN1 | STN1 subunit of CST complex | Major susceptibility factor in |
| ATP11A | ATPase phospholipid transporting 11A | Major susceptibility factor in |
| DPP9 | dipeptidyl peptidase 9 | Major susceptibility factor in |
| PARN | poly(A)-specific ribonuclease | Major susceptibility factor in |
临床表型 20
极常见 99–80%1
- 肺间质形态异常 HP:0006530
常见 79–30%16
- 手足发绀 HP:0001063
- 支气管扩张 HP:0002110
- 杵状指 HP:0100759
- 咳嗽 HP:0012735
- 肺啰音 HP:0030830
- 一氧化碳弥散量减少 HP:0045051
- 劳力性呼吸困难 HP:0002875
- 疲乏 HP:0012378
- 胃食管反流 HP:0002020
- 毛玻璃样结构 HP:0025179
- 蜂窝状肺 HP:0025175
- 肺纤维化 HP:0002206
- 用力肺活量降低 HP:0032341
- 肺部HRCT可见网状结构 HP:0025390
- 胸膜下蜂窝状结构 HP:0031631
- 寻常性间质性肺炎 HP:0031950
偶见 29–5%3
- 运动不耐受 HP:0003546
- 直立低氧血症 HP:0033367
- 肺动脉反流 HP:0010444
近两年的全球研究 8,181L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-08Body composition is associated with nintedanib-related diarrhoea: risk stratification in idiopathic pulmonary fibrosis
- 2026-08Optimal timing, duration and sequencing of therapy for progressive pulmonary fibrosis: the urgent need to move beyond the 'wait-to-fail' paradigm
- 2026-08Comprehensive assessment of complete blood count as a prognostic biomarker in interstitial lung diseases
- 2026-08IGF2BP3 promotes early angiogenesis in pulmonary fibrosis by stabilizing HIF-1α
- 2026-08Pharmacokinetics and Safety of Nerandomilast in Healthy Volunteers
- 2026-08Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the French Pulmonary Hypertension Registry
- 2026-08Large Language Models for Classifying Usual Interstitial Pneumonia from Radiology Reports: Native Reasoning Versus Structured Prompting
- 2026-08Integrative single‑cell and bulk transcriptomic profiling reveals MMP1 as a core effector and CTSB as a putative collaborator in ATBC‑aggravated pulmonary fibrosis
- 2026-08The Gut Speaks to the Lung: Fecal Microbiota and Survival in Idiopathic Pulmonary Fibrosis
- 2026-08Human Embryonic Stem Cell-Derived Immunity-And-Matrix-Regulatory Cells Attenuate Pulmonary Fibrosis via MMP1-Mediated Collagen Degradation
- 2026-08综述Theranostic innovation in infectious lung diseases: integrating biotechnology and nanotechnology for precision medicine
- 2026-08Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real-world data from the ILD-PRO Registry
- 2026-08Numb Mediates IL-1β/TGF-β1-Driven Inflammation-Fibrosis Coupling in Idiopathic Pulmonary Fibrosis
- 2026-08综述Distinguishing true from false idiopathic pulmonary fibrosis: Progress in biomarkers for early identification of rheumatoid arthritis
- 2026-08Metabolic Control of Alveolar Epithelial Regeneration: Implications for Lung Repair and Pulmonary Fibrosis
- 2026-08BCL9 inhibition promotes fibroblast lipogenesis by regulating macrophage-fibroblast interactions to attenuate pulmonary fibrosis
- 2026-08Mannose-modified tobacco mosaic virus-mediated macrophage regulation inhibits pulmonary fibrosis progression
- 2026-08综述A self-sustaining repair circuit drives the progression of pulmonary fibrosis
- 2026-08Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?
- 2026-08综述The interplay of airway epithelium and biomechanical stress in pulmonary fibrosis
国家医保药品目录中点名本病的药品 2L2
出自《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（医保发〔2025〕33号，2026-01-01 起执行）。下列药品在药品名称或限定支付范围里出现了本病的名称。
匹配不到 ≠ 不能报销。目录里只有约一成药品设了限定支付范围，其余按适应症正常使用同样可报销；本区块只能回答「目录有没有点名这个病」，不能回答「这个病有没有药能报销」。各省执行细则、双通道与单独支付范围另有规定，请以当地医保部门口径为准。
- 乙磺酸尼达尼布软胶囊乙类西药限：1.特发性肺纤维化(IPF)；2.系统性硬化病相关间质性肺疾病(SSc-ILD)；3.具有进行性表型的慢性纤维化性间质性肺疾病。
- 吡非尼酮 口服常释剂型乙类西药限特发性肺纤维化。
境外已获批用于本病的药物 6L2
欧盟 3 项、美国 3 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Ofev欧盟2015-01-14nintedanib官方记录
- Pirfenidone axunio (previously Pirfenidone AET)欧盟2022-06-20pirfenidone官方记录
- Jascayd欧盟2026-07-15nerandomilast官方记录
- ESBRIET美国2014-10-15pirfenidone官方记录
- OFEV美国2014-10-15nintedanib官方记录
- Jascayd美国2025-10-07nerandomilast官方记录
已获孤儿药资格、尚未获批的在研药物（96 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Interferon gamma欧盟2007-10-29Treatment of idiopathic pulmonary fibrosis官方记录
- 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,欧盟2010-11-26Treatment of idiopathic pulmonary fibrosis官方记录
- recombinant human pentraxin-2欧盟2012-07-17Treatment of idiopathic pulmonary fibrosis官方记录
- Humanised anti-alpha ν beta 6 monoclonal antibody欧盟2014-07-29Treatment of idiopathic pulmonary fibrosis官方记录
- 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid (lanif欧盟2014-11-19Treatment of idiopathic pulmonary fibrosis官方记录
- 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N欧盟2016-07-14Treatment of idiopathic pulmonary fibrosis官方记录
- tilorone欧盟2018-08-24Treatment of idiopathic pulmonary fibrosis官方记录
- treprostinil sodium欧盟2022-03-16Treatment of idiopathic pulmonary fibrosis官方记录
- chimeric peptide of human glucagon-like peptide-1, glucagon and gastri欧盟2022-05-16Treatment of idiopathic pulmonary fibrosis官方记录
- Pirfenidone欧盟2022-06-24Treatment of idiopathic pulmonary fibrosis官方记录
- (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)bu欧盟2022-12-09Treatment of idiopathic pulmonary fibrosis官方记录
- bersiporocin欧盟2023-12-13Treatment of idiopathic pulmonary fibrosis官方记录
- taladegib欧盟2025-05-22Treatment of idiopathic pulmonary fibrosis官方记录
- tranilast欧盟2025-05-22Treatment of idiopathic pulmonary fibrosis官方记录
- admilparant欧盟2025-08-22Treatment of idiopathic pulmonary fibrosis官方记录
- adeno-associated virus vector serotype 6.2 containing human TERT gene欧盟2025-09-12Treatment of idiopathic pulmonary fibrosis官方记录
- deupirfenidone欧盟2026-01-09Treatment idiopathic pulmonary fibrosis官方记录
- Phe-Thr-Thr-Phe-Thr-Val-Thr欧盟2026-01-09Treatment of idiopathic pulmonary fibrosis官方记录
- Interferon gamma美国2007-10-11Treatment of idiopathic pulmonary fibrosis官方记录
- ammonium tetrathiomolybdate美国2008-05-05Treatment of idiopathic pulmonary fibrosis官方记录
- purified bovine type collagen美国2009-04-27Treatment of idiopathic pulmonary fibrosis官方记录
- Cintredekin Besudotox美国2010-04-30Treatment of idiopathic pulmonary fibrosis官方记录
- humanized monoclonal antibody against human integrin alphaVbeta6美国2010-08-05Treatment of idiopathic pulmonary fibrosis官方记录
- 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,美国2010-09-21Treatment of idiopathic pulmonary fibrosis.官方记录
- Sar9, Met(O2)11-Substance P美国2011-03-16Treatment of idiopathic pulmonary fibrosis官方记录
- (R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methy美国2011-04-15Treatment of idiopathic pulmonary fibrosis官方记录
- pirfenidone美国2014-07-31Treatment of idiopathic pulmonary fibrosis官方记录
- tipelukast美国2014-10-20Treatment of idiopathic pulmonary fibrosis官方记录
- lebrikizumab美国2015-03-09Treatment of idiopathic pulmonary fibrosis官方记录
- tetra-substituted porphyrin derivative containing manganese (III)美国2015-03-16Treatment of idiopathic pulmonary fibrosis官方记录
- monoclonal antibody targeting eotaxin-2美国2015-10-29Treatment of idiopathic pulmonary fibrosis.官方记录
- carbon monoxide美国2016-08-16Treatment of idiopathic pulmonary fibrosis (IPF).官方记录
- 3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(美国2017-01-25Treatment of idiopathic pulmonary fibrosis官方记录
- nitric oxide美国2017-01-31Treatment of idiopathic pulmonary fibrosis官方记录
- yinfenidone美国2017-08-10Treatment of idiopathic pulmonary fibrosis官方记录
- plasminogen (Human)美国2017-12-14Treatment of idiopathic pulmonary fibrosis (IPF)官方记录
- 6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,美国2018-04-04Treatment of Idiopathic Pulmonary Fibrosis官方记录
- N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1美国2018-05-23Treatment of Idiopathic pulmonary fibrosis (IPF)官方记录
- soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)(美国2018-07-09Treatment of idiopathic pulmonary fibrosis (IPF)官方记录
- small molecule inhibitor of integrins avb6 and avb1美国2018-08-01Treatment of Idiopathic Pulmonary Fibrosis官方记录
另有 56 项未列出。
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 71L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 21
- 招募中NCT06125327SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 1 个：Beijing
- 招募中NCT06267183A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.中国研究中心 1 个：Shanghai
- 招募中NCT06238622A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast中国研究中心 37 个：Beijing、Changsha、Chengdu、Guangzhou、Hangzhou、Hefei 等 23 地
- 仅邀请入组NCT06629623Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Beijing
- 尚未开始招募NCT06922916Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study中国研究中心 1 个：Hangzhou
- 尚未开始招募NCT07019714Daoyin Technique for Improving Exercise Endurance in IPF中国研究中心 1 个：Shenyang
- 尚未开始招募NCT06914713Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF中国研究中心 1 个：Zhengzhou
- 尚未开始招募NCT07131150Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis中国研究中心 22 个：Beijing、Changchun、Changsha、Chengdu、Guangzhou、Hebei 等 15 地
- 尚未开始招募NCT07162870Idiopathic Pulmonary Fibrosis Cohort of TCM中国研究中心 1 个：Zhengzhou
- 尚未开始招募NCT07178392Disease-syndrome Characteristics of IPF中国研究中心 1 个：Zhengzhou
- 招募中NCT07082842Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF中国研究中心 1 个：Beijing
- 招募中NCT07121413A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis中国研究中心 12 个：Chengdu、Guangzhou、Hangzhou、Nanchang、Nanjing、Neimeng 等 10 地
- 招募中NCT07464912A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 1 个：Beijing
- 尚未开始招募NCT07359963Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy中国研究中心 1 个：Yiwu
- 招募中NCT07447102Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Shanghai
- 尚未开始招募NCT07515066Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Beijing
- 尚未开始招募NCT07593690A Phase I Study of HW241045 in Healthy Subjects中国研究中心 1 个：Jinan
- 招募中NCT07652658A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.中国研究中心 13 个：Beijing、Changchun、Changsha、Chengdu、Guangzhou、Lanzhou 等 13 地
- 尚未开始招募NCT07687459Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 47 个：Anyang、Beijing、Changchun、Changsha、Chengdu、Fuzhou 等 33 地
- 尚未开始招募NCT07719023A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Beijing
- 尚未开始招募NCT07441408Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis中国研究中心 40 个：Beijing、Changsha、Chengdu、Guangzhou、Hangzhou、Hefei 等 26 地
其他状态的试验（50 项）
- 已完成NCT00514683Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis中国研究中心 5 个：Beijing、Nanjing、Shanghai、Shenyang
- 已完成NCT01170065Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 4 个：Beijing、Nanjing、Shanghai
- 已完成NCT01335464Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients中国研究中心 6 个：Beijing、Changsha、Chengdu、Nanchang、Xi'an
- 已完成NCT01335477Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II中国研究中心 8 个：Beijing、Shanghai、Shenyang、Yinchuan
- 状态未知NCT01504334Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)中国研究中心 1 个：Beijing
- 已完成NCT01619085Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis中国研究中心 11 个：Beijing、Changsha、Chengdu、Nanchang、Shanghai、Shenyang 等 8 地
- 状态未知NCT0248588668Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Beijing
- 状态未知NCT02509364Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)中国研究中心 1 个：Shanghai
- 已完成NCT02745184Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Shanghai
- 状态未知NCT03666234Idiopathic Pulmonary Fibrosis Registry China Study中国研究中心 1 个：Beijing
- 已完成NCT03619616Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults中国研究中心 1 个：Changsha
- 已完成NCT03711435Traditional Chinese Medicine(TCM) Syndrome Classification of Idiopathic Pulmonary Fibrosis(IPF) and Metabolomics中国研究中心 1 个：Xuzhou
- 已终止NCT03955146Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 22 个：Beijing、Changsha、Chengdu、Dalian、Guangzhou、Hangzhou 等 16 地
- 已完成NCT05146934The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial Intelligence中国研究中心 1 个：Beijing
- 已完成NCT04512170Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects中国研究中心 1 个：Shanghai
- 已完成NCT04419506A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 5 个：Beijing、Changchun、Chengdu、Shanghai
- 已完成NCT04308681A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis中国研究中心 4 个：Beijing、Shanghai、Wuhan
- 状态未知NCT04511884Screening Microorganism of Cryptogenic Mechanical Pneumonia Through Next Generation Sequencing to Lung Tissue Fluid中国研究中心 2 个：Shanghai
- 状态未知NCT04187690Jin-shui Huan-xian Granule in the Treatment of IPF中国研究中心 1 个：Zhengzhou
- 已完成NCT04312594Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Beijing
- 已终止NCT04419558Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 15 个：Beijing、Chengdu、Guangzhou、Hangzhou、Shanghai、Shenyang 等 10 地
- 已终止NCT04552899A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis中国研究中心 31 个：Beijing、Changsha、Chengdu、Guangdong Province Guangzhou City、Guangzhou、Hangzhou 等 20 地
- 已完成NCT06160440The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.中国研究中心 1 个：Guangzhou
- 已完成NCT05383131To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers中国研究中心 1 个：Shanghai
- 已完成NCT07588646Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects中国研究中心 1 个：Shanghai
- 进行中·不再招募NCT05060822Phase ll Study of HEC585 in Patients With IPF中国研究中心 1 个：Beijing
- 已完成NCT05657184Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001中国研究中心 3 个：Beijing、Guangzhou、Shanghai
- 已完成NCT04986540A Trial of SHR - 1906 in Healthy Subjects中国研究中心 1 个：Jinan
- 已终止NCT04594707A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis中国研究中心 10 个：Beijing、Changsha、Shenyang、Shijiazhuang、Tianjin、Wuhan 等 8 地
- 进行中·不再招募NCT05828953Anlotinib Capsules in the Treatment for IPF/PF-ILDs中国研究中心 1 个：Wenzhou
- 已完成NCT05119972Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）中国研究中心 1 个：Shanghai
- 状态未知NCT05424887A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Beijing
- 已完成NCT06135363Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects中国研究中心 1 个：Shanghai
- 已完成NCT05321069A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 33 个：Beijing、Changsha、Chengdu、Guangzhou、Hangzhou、Hefei 等 21 地
- 已完成NCT05468502Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 1 个：Shanghai
- 已完成NCT05722964Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis中国研究中心 1 个：Beijing
- 已完成NCT05895565A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects中国研究中心 7 个：Beijing、Guangzhou、Hefei、Nanjing、Shanghai、Wuhan
- 已完成NCT05938920Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)中国研究中心 22 个：Beijing、Changsha、Chengdu、Guangzhou、Haikou、Hangzhou 等 15 地
- 状态未知NCT05912049A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects中国研究中心 1 个：Suzhou
- 已完成NCT06589921Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions中国研究中心 1 个：Qingdao
另有 10 项未列出。
中国境外的在招试验 115L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国37加拿大9英国9澳大利亚8意大利8西班牙7德国6韩国6日本4法国4新西兰3阿根廷3比利时3丹麦3另有 19 个国家/地区
CT.gov 报告命中 115 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07674745Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis美国
- 尚未开始招募NCT07723638New Diagnostic Approaches in the Management of Inflammatory Lung Diseases
- 尚未开始招募NCT07728721Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis
- 尚未开始招募NCT07520110Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis美国
- 尚未开始招募NCT07673237Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring美国
- 尚未开始招募NCT07722507Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis日本
- 招募中NCT07743996Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study日本
- 招募中NCT05988463Dose-Escalation Study of Artesunate Patients With IPF美国
- 尚未开始招募NCT07728448Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms
- 招募中NCT07516951A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary FibrosisNorth Macedonia
- 尚未开始招募NCT07613216A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension美国
- 尚未开始招募NCT07600021A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis
- 招募中NCT07679893Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis加拿大
- 尚未开始招募NCT07682337Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects澳大利亚
- 招募中NCT07671911Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets美国
外部标识与链接
OrphanetOMIM:178500OMIM:616371OMIM:616373MONDO:800504GARD:8609ICD-10 J84.1ICD-11 CB03.4ClinicalTrials.gov 检索
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）